A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders
ConclusionFor a naïve patient in the new DAA era, the PegIFN/RBV treatment might be conserved for those with all favorable risk parameters, considering the treatment duration and cost per SVR, in the resource-constrained countries.
Source: Journal of the Chinese Medical Association - Category: General Medicine Source Type: research
More News: Chia | China Health | Databases & Libraries | General Medicine | Health Insurance | Hepatitis | Hepatitis C | Insurance | Study | Taiwan Health